| Literature DB >> 32523973 |
Dong Youn Kim1, Uh Jin Kim2, Yohan Yu2, Seong-Eun Kim2, Seung-Ji Kang2, Kang-Il Jun1, Chang Kyung Kang1, Kyoung-Ho Song1, Pyoeng Gyun Choe1, Eu Suk Kim1, Hong Bin Kim1, Hee-Chang Jang2, Sook In Jung2, Myoung-Don Oh1, Kyung-Hwa Park2, Nam Joong Kim1.
Abstract
BACKGROUND: It is difficult to select an appropriate empirical antibiotic treatment regimen for patients with culture-negative pyogenic vertebral osteomyelitis (PVO). Having knowledge of the distribution of microorganisms according to patient characteristics can help clinicians make informed choices regarding empirical antibiotics. The aim of this study was to determine the microbial distribution among individuals with PVO according to their demographic and clinical characteristics.Entities:
Keywords: Staphylococcus aureus; chronic renal insufficiency; gram-negative bacteria; spondylitis; vertebral osteomyelitis
Year: 2020 PMID: 32523973 PMCID: PMC7270706 DOI: 10.1093/ofid/ofaa176
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Demographic and Clinical Characteristics of 586 Patients With Pyogenic Vertebral Osteomyelitis
| Patient Characteristic | Patients |
|---|---|
| Age, mean ± SD, y | 65.1 ± 12.5 |
| Male | 371 (63.3) |
| Comorbidity | |
| Diabetes mellitus | 180 (30.7) |
| Solid tumora | 84 (14.3) |
| Chronic renal disease | 61 (10.4) |
| Cirrhosis | 55 (9.4) |
| Cerebrovascular disease | 39 (6.6) |
| Congestive heart failure | 29 (4.9) |
| Immunosuppressantb | 28 (4.8) |
| Hematologic malignancy | 14 (2.4) |
| Blunt trauma | 14 (2.4) |
| Spinal location | |
| Cervical spine | 40 (6.8) |
| Thoracic spine | 115 (19.6) |
| Lumbar spine | 387 (66.0) |
| Sacrum | 44 (7.5) |
| Predisposing condition | |
| Epidural block | 111 (18.9) |
| Vertebroplasty | 19 (3.2) |
| No. of vertebrae involved | |
| ≤2 | 471 (80.4) |
| ≥3 | 115 (19.6) |
| Concomitant infective endocarditis | 42 (7.2) |
| Etiology | |
| | 255 (43.5) |
| MSSA | 157 (26.8) |
| MRSA | 98 (16.7) |
| MSCNS | 12 (2.0) |
| MRCNS | 19 (3.2) |
| | 22 (3.8) |
| | 118 (20.1) |
| Gram-negative bacilli | 130 (22.2) |
| Anaerobes | 11 (1.9) |
| Polymicrobial | 9 (1.5) |
| Otherc | 10 (1.7) |
Data are presented as No. (%) of patients unless otherwise indicated.
Abbreviations: MRCNS, methicillin-resistant coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-sensitive coagulase-negative Staphylococcus; MSSA, methicillin-sensitive Staphylococcus aureus.
aActive localized or metastatic solid tumor.
bCorticosteroids (>10 mg of prednisolone daily within 4 weeks), cytoreductive agents, immunophilin binding agents, mycophenolate, anti–tumor necrosis factor agents, or other monoclonal antibodies.
cThe other bacteria (count) were Ralstonia mannitolilytica (1), Listeria monocytogenes (1), Stenotrophomonas maltophilia (1), Burkholderia cepacia (1), Neisseria species (2), Granulicatella adiacens (1), Lactococcus gravieae (2), and Erysipelothrix rhusiopathiae (1).
Distribution of Etiologic Microorganisms in Patients With Pyogenic Vertebral Osteomyelitis According to Age, Sex, and Spinal Level
| Cervical Spine | Cervical Spine | Lumbar Spine | Sacrum | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, y | Organism | Males (n = 33) | Females (n = 7) | Males (n = 77) | Females (n = 38) | Males (n = 236) | Females (n = 151) | Males (n = 25) | Females (n = 19) | Males (n = 371) | Females (n = 215) |
| <60 | Total | ||||||||||
| MSSA | 6 (50.0) | 1 (25.0) | 9 (52.9) | 5 (83.3) | 22 (43.1) | 8 (25.0) | 4 (36.4) | 2 (66.7) | 41 (45.1) | 16 (35.6) | |
| MRSA | 1 (8.3) | 1 (25.0) | 5 (29.4) | 0 (0) | 3 (5.9) | 4 (12.5) | 2 (18.2) | 0 (0) | 11 (12.1) | 5 (11.1) | |
| MSCNS | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3.1) | 0 (0) | 0 (0) | 0 (0) | 1 (2.2) | |
| MRCNS | 0 (0) | 1 (25.0) | 0 (0) | 0 (0) | 3 (5.9) | 2 (6.3) | 0 (0) | 0 (0) | 3 (3.3) | 3 (6.7) | |
|
| 1 (8.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | 0 (0) | |
|
| 2 (16.7) | 0 (0) | 1 (5.9) | 0 (0) | 16 (31.4) | 7 (21.9) | 3 (27.3) | 0 (0) | 22 (24.2) | 7 (15.6) | |
| Gram-negative bacilli | 0 (0) | 1 (25.0) | 2 (11.8) | 1 (16.7) | 5 (9.8) | 10 (31.3) | 0 (0) | 1 (33.3) | 7 (7.7) | 13 (28.9) | |
| Anaerobes | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (3.9) | 0 (0) | 2 (18.2) | 0 (0) | 4 (4.4) | 0 (0) | |
| Polymicrobial | 2 (16.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (2.2) | 0 (0) | |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| 60–75 | Total | ||||||||||
| MSSA | 7 (38.9) | 0 (0) | 14 (33.3) | 5 (25.0) | 28 (20.6) | 15 (18.1) | 4 (36.4) | 5 (33.3) | 53 (25.6) | 25 (20.8) | |
| MRSA | 5 (27.8) | 1 (50.0) | 10 (23.8) | 4 (20.0) | 32 (23.5) | 10 (12.0) | 0 (0) | 2 (13.3) | 47 (22.7) | 17 (14.2) | |
| MSCNS | 1 (5.6) | 0 | 2 (4.8) | 0 (0) | 3 (2.2) | 1 (1.2) | 0 (0) | 0 (0) | 6 (2.9) | 1 (0.8) | |
| MRCNS | 0 (0) | 0 (0) | 1 (2.4) | 0 (0) | 3 (2.2) | 5 (6.0) | 0 (0) | 0 (0) | 4 (1.9) | 5 (4.2) | |
|
| 0 (0) | 0 (0) | 0 (0) | 1 (5.0) | 8 (5.9) | 3 (3.6) | 1 (9.1) | 0 (0) | 9 (4.3) | 4 (3.3) | |
|
| 1 (5.6) | 0 (0) | 5 (11.9) | 2 (10.0) | 36 (26.5) | 17 (20.5) | 3 (27.3) | 4 (26.7) | 45 (21.7) | 23 (19.2) | |
| Gram-negative bacilli | 1 (5.6) | 1 (50.) | 9 (21.4) | 8 (40.0) | 23 (16.9) | 27 (32.5) | 2 (18.2) | 1 (6.7) | 35 (16.9) | 37 (30.8) | |
| Anaerobes | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | 0 (0) | 1 (9.1) | 2 (13.3) | 3 (1.4) | 2 (1.7) | |
| Polymicrobial | 1 (5.6) | 0 (0) | 1 (2.4) | 0 (0) | 1 (0.7) | 1 (1.2) | 0 (0) | 1 (6.7) | 3 (1.4) | 2 (1.7) | |
| Other | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) | 1 (0.7) | 4 (4.8) | 0 (0) | 0 (0) | 2 (1.0) | 4 (3.3) | |
| >75 | Total | ||||||||||
| MSSA | 1 (33.3) | 0 (0) | 6 (33.3) | 1 (8.3) | 9 (18.4) | 4 (11.1) | 0 (0) | 1 (100) | 16 (21.9) | 6 (12.0) | |
| MRSA | 0 (0) | 0 (0) | 2 (11.1) | 2 (16.7) | 5 (10.2) | 7 (19.4) | 2 (66.7) | 0 (0) | 9 (12.3) | 9 (18.0) | |
| MSCNS | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 3 (6.1) | 0 (0) | 0 (0) | 0 (0) | 3 (4.1) | 1 (2.0) | |
| MRCNS | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 0 (0) | 3 (8.3) | 0 (0) | 0 (0) | 0 (0) | 4 (8.0) | |
|
| 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 5 (10.2) | 2 (5.6) | 0 (0) | 0 (0) | 6 (8.2) | 2 (4.0) | |
|
| 2 (66.7) | 0 (0) | 5 (27.8) | 1 (8.3) | 7 (14.3) | 6 (16.7) | 0 (0) | 0 (0) | 14 (19.2) | 7 (14.0) | |
| Gram-negative bacilli | 0 (0) | 1 (100) | 3 (16.7) | 5 (41.7) | 15 (30.6) | 13 (36.1) | 1 (33.3) | 0 (0) | 19 (26.0) | 19 (38.0) | |
| Anaerobes | 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) | 1 (2.8) | 0 (0) | 0 (0) | 1 (1.4) | 1 (2.0) | |
| Polymicrobial | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 1 (2.0) | 0 (0) | 0 (0) | 0 (0) | 1 (1.4) | 1 (2.0) | |
| Other | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (8.2) | 0 (0) | 0 (0) | 0 (0) | 4 (5.5) | 0 (0) | |
Data are presented as No. (%) of patients unless otherwise indicated.
Abbreviations: MRCNS, methicillin-resistant coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-sensitive coagulase-negative Staphylococcus; MSSA, methicillin-sensitive Staphylococcus aureus.
Figure 1.Microbial etiology of pyogenic vertebral osteomyelitis according to age (A), sex (B), and spinal level (C).
Distribution of Etiologic Microorganisms in Patients With Pyogenic Vertebral Osteomyelitis According to Comorbidities
| Patients With DM (n = 180) | Patients Without DM (n = 406) |
| Patients With LC (n = 55) | Patients Without LC (n = 531) |
| Patients With CRD (n = 61) | Patients Without CRD (n = 525) |
| Patients With Solid Tumor (n = 84) | Patients Without Solid Tumor (n = 502) |
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 84 (46.7) | 171 (42.1) | .306 | 14 (25.5) | 241 (45.4) | .005 | 32 (52.5) | 223 (42.5) | .14 | 27 (32.1) | 228 (45.4) | .023 |
| MSSA | 49 (27.2) | 108 (26.6) | .876 | 10 (18.2) | 147 (27.7) | .130 | 11 (18.0) | 146 (27.8) | .103 | 14 (16.7) | 143 (28.5) | .024 |
| MRSA | 35 (19.4) | 63 (15.5) | .240 | 4 (7.3) | 94 (17.7) | .048 | 21 (34.4) | 77 (14.7) | <.001 | 13 (15.5) | 85 (16.9) | .741 |
| MSCNS | 3 (1.7) | 9 (2.2) | .764 | 1 (1.8) | 11 (2.1) | 1.000 | 1 (1.6) | 11 (2.1) | >.99 | 3 (3.6) | 9 (1.8) | .394 |
| MRCNS | 5 (2.8) | 14 (3.4) | .672 | 2 (3.6) | 17 (3.2) | .696 | 1 (1.6) | 18 (3.4) | .709 | 1 (1.2) | 18 (3.6) | .500 |
|
| 10 (5.6) | 12 (3.0) | .127 | 0 (0) | 22 (4.1) | .252 | 5 (8.2) | 17 (3.2) | .068 | 1 (1.2) | 21 (4.2) | .346 |
|
| 34 (18.9) | 84 (20.7) | .616 | 16 (29.1) | 102 (19.2) | .082 | 10 (16.4) | 108 (20.6) | .441 | 23 (27.4) | 95 (18.9) | .074 |
| Gram-negative bacilli | 37 (20.6) | 93 (22.9) | .527 | 18 (32.7) | 112 (21.1) | .048 | 10 (16.4) | 120 (22.9) | .250 | 26 (31.0) | 104 (20.7) | .037 |
| Anaerobes | 3 (1.7) | 8 (2.0) | 1.000 | 3 (5.5) | 8 (1.5) | .075 | 0 (0) | 11 (2.1) | .615 | 0 (0) | 11 (2.2) | .379 |
| Polymicrobial | 2 (1.1) | 7 (1.7) | .729 | 1 (1.8) | 8 (1.5) | .591 | 2 (3.3) | 7 (1.3) | .239 | 2 (2.4) | 7 (1.4) | .624 |
| Other | 2 (1.1) | 8 (2.0) | .731 | 0 (0) | 10 (1.9) | .610 | 0 (0) | 10 (1.9) | .610 | 1 (1.2) | 9 (1.8) | >.99 |
Data are presented as No. (%) of patients unless otherwise indicated.
Abbreviations: CRD, chronic renal disease; DM, diabetes mellitus; LC, liver cirrhosis; MRCNS, methicillin-resistant coagulase-negative; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-sensitive coagulase-negative Staphylococcus; MSSA, methicillin-sensitive Staphylococcus aureus.
aActive localized or metastatic solid tumor.
Causative Pathogens of Pyogenic Vertebral Osteomyelitis in Patients With or Without Spinal Procedures
| Organism | Patients With Previous Spinal Procedures (n = 128) | Patients Without Previous Spinal Procedures (n = 458) |
|
|---|---|---|---|
|
| 48 (37.5) | 207 (45.2) | .120 |
| MSSA | 33 (25.8) | 124 (27.1) | .770 |
| MRSA | 15 (11.7) | 83 (18.1) | .086 |
| MSCNS | 3 (2.3) | 9 (2.0) | .730 |
| MRCNS | 11 (8.6) | 8 (1.7) | .001 |
|
| 6 (4.7) | 16 (3.5) | .598 |
|
| 28 (21.9) | 90 (19.7) | .579 |
| G(-) bacilli | 23 (18.0) | 107 (23.4) | .194 |
| Anaerobes | 3 (2.3) | 8 (1.7) | .712 |
| Polymicrobial | 1 (0.8) | 8 (1.7) | .692 |
| Other | 5 (3.9) | 5 (1.1) | .045 |
Data are presented as No. (%) of patients unless otherwise indicated.
Abbreviations: MRCNS, methicillin-resistant coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-sensitive coagulase-negative Staphylococcus; MSSA, methicillin-sensitive Staphylococcus aureus.